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Background: This study was conducted to evaluate the safety and efficacy of adding a fixed 
combination of brinzolamide 1%/timolol 0.5% to prostaglandin analog (PGA) monotherapy in 
patients with primary open-angle glaucoma, pigment dispersion glaucoma, or ocular hypertension 
who require additional intraocular pressure (IOP) reduction.
Methods: This was a prospective, multicenter (n = 5), open-label, single-arm, Phase IV clinical 
trial in which patients currently being treated with a PGA but requiring additional IOP reduction 
were administered brinzolamide 1%/timolol 0.5% twice daily as adjunctive therapy to their 
current PGA monotherapy regimen. The primary objective was to examine the IOP-lowering 
efficacy of brinzolamide-timolol when used as adjunctive therapy.
Results: Forty-seven patients enrolled in and completed the study. After 12 weeks of adjunctive 
brinzolamide-timolol therapy, the mean IOP of the total patient population decreased from 22.1 mmHg 
at baseline to 16.7 mmHg. The mean IOP reduction of 5.4 mmHg (24.4%) was both clinically and 
statistically significant (P , 0.001). This significant decrease in mean IOP at week 12 was maintained 
across all PGA groups (P , 0.05). No significant differences were observed in symptom frequency 
between baseline and week 12 for any of the six solicited symptoms. A total of 17 adverse events from 
six patients was reported, of which ten were drug-related. Most (n = 7) of the drug-related adverse 
events were mild or moderate in intensity. None of the adverse events required any treatment or resulted 
in treatment interruption or discontinuation. Of the 90 eligible eyes, 85.6% had a decrease in IOP of 
at least 3 mmHg from baseline and 98% of patients had a decrease in IOP of $1 mmHg.
Conclusion: This study suggests that a fixed combination of brinzolamide 1%/timolol 0.5% 
can provide additional IOP reduction effectively and safely when used as adjunctive therapy for 
patients receiving insufficient IOP reduction from PGA monotherapy.
Keywords: adjunctive therapy, brinzolamide, carbonic anhydrase inhibitor, fixed combination, 
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Introduction
Prostaglandin analogs (PGAs) are one of the most common first-line therapies used 
to reduce intraocular pressure (IOP).1 While PGAs can reduce IOP by approximately 
30% (6–8 mmHg),2–4 patients will often require a further decrease to achieve an 
individually set target IOP. In such cases, a stepwise approach is typically used in which 
a single hypotensive agent, such as a beta-blocker, a carbonic anhydrase inhibitor, or 
an alpha-agonist, is added to therapy.1 Replacing the PGA with a fixed combination 
of a PGA + a beta-blocker has produced an additional 13.7%–22.6% decrease in IOP 
compared with PGA monotherapy alone.5,6 However, other fixed combinations have 
also been used as adjunctive therapy, effectively progressing a patient directly to a 
three-drug regimen.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Brinzolamide 1%/timolol 0.5% (Azarga®, Alcon Pharma 
GmbH, Puurs, Belgium) is a fixed-combination product that 
combines a carbonic anhydrase inhibitor with a beta-blocker. 
Brinzolamide-timolol was recently approved in the European 
Union for the treatment of primary open-angle glaucoma 
or ocular hypertension in patients for whom monotherapy 
provides insufficient IOP reduction.7 Brinzolamide-timolol 
has been shown to produce both statistically and clinically 
superior reductions in IOP from baseline (8.0–8.7 mmHg) 
compared with either brinzolamide 1% alone (5.1–5.6 mmHg) 
or timolol 0.5% alone (5.7–6.9 mmHg).8 It has also 
demonstrated noninferior IOP-lowering efficacy and less 
ocular discomfort when compared with a fixed combination 
of dorzolamide 2%/timolol 0.5% in patients with open-angle 
glaucoma or ocular hypertension.9,10 However, since   clinical 
data on the use of brinzolamide-timolol as adjunctive therapy 
are lacking, a study was conducted to evaluate the safety and 
efficacy of adding brinzolamide-timolol to PGA   monotherapy 
in patients with either primary open-angle glaucoma, pigment 
dispersion glaucoma, or ocular hypertension who require 
further IOP reduction.
Methods
This was a prospective, multicenter (five sites throughout 
Germany), open-label, single-arm Phase IV clinical trial 
in which patients currently being treated with a PGA but 
requiring additional reduction in IOP were administered 
brinzolamide 1%/timolol 0.5% twice daily in addition to 
their current PGA monotherapy regimen. The protocol was 
approved by the ethics committee of the Landesärztekammer 
Rheinland Pfalz in Mainz and the study was performed in 
compliance with the ethical principles of the Declaration 
of Helsinki and Good Clinical Practice. All participating 
patients provided their written informed consent.
Patients
Eligible patients were at least 21 years old with a diagnosis 
of primary open-angle glaucoma, pigment dispersion 
glaucoma, or ocular hypertension in at least one eye. If both 
eyes qualified for the study, both were treated and analyzed 
using an average eye analysis. Patients must have been treated 
with PGA monotherapy for at least 4 weeks prior to visit 1 
(baseline visit), and IOP had to be at least 20 mmHg in the 
qualifying eye(s) but no more than 35 mmHg in both eyes 
while receiving treatment with PGA monotherapy. IOP in 
both eyes had to be considered safe by the   investigator 
to assure clinical stability of vision and the optic nerve 
  throughout the duration of the trial. Patients were required 
to have a best-corrected Snellen visual acuity of at least 
20/200 in both eyes.
Patients were excluded if they met any of the following 
criteria: presence of any primary or secondary glaucoma not 
listed in the inclusion criteria; presence of extreme narrow 
angle with complete or partial closure in either eye, as 
measured by gonioscopy; any abnormality preventing reliable 
applanation tonometry in qualifying eye(s); presence of 
corneal dystrophies; any opacity or patient uncooperativeness 
that restricts adequate examination of the ocular fundus 
or anterior chamber of either eye; concurrent infectious/
noninfectious conjunctivitis, keratitis or uveitis in either eye; 
intraocular conventional surgery or laser surgery in qualifying 
eye(s) less than 3 months prior to visit 1; risk of visual field or 
visual acuity worsening as a consequence of trial participation 
in the investigator’s opinion; progressive retinal or optic 
nerve disease from any cause apart from glaucoma; women 
of childbearing potential not using reliable means of birth 
control or who were pregnant or lactating; any clinically 
significant, serious, or severe medical or psychiatric condition; 
a condition, which, in the opinion of the investigator, would 
interfere with trial participation or would present a significant 
risk to the patient; participation in any other investigational 
study within 30 days prior to visit 1; use of systemic 
medications known to affect IOP (eg, oral beta-adrenergic 
blockers, alpha-agonists and alpha-blockers, angiotensin-
converting enzyme inhibitors, and calcium channel blockers) 
without being changed for at least 7 days prior to visit 1 or an 
anticipated change in the dosage/regimen during the course 
of the study; use of systemic carbonic anhydrase inhibitors 
(eg, methazolamide, acetazolamide); current or anticipated 
use of systemic corticosteroids, by any route except inhaled, 
for longer than 2 weeks during the trial; severe allergic 
rhinitis; hypersensitivity to beta-blockers other than timolol; 
severely impaired renal function; hyperchloremic acidosis; 
bronchial asthma or a history of bronchial asthma, bronchial 
hyperreactivity, or severe chronic obstructive pulmonary 
disease that would preclude the safe administration of a topical 
beta-blocker; sinus bradycardia (,55 bpm), second-degree 
or third-degree atrioventricular block, sinoatrial block, overt 
cardiac failure, or cardiogenic shock that would preclude safe 
administration of a topical beta-blocker; history of myasthenia 
gravis, allergy to sulfur, ocular herpes simplex, allergy or 
sensitivity to any components of the preparations to be used 
in this trial deemed clinically significant in the opinion of 
the investigator; history of, or at risk for, uveitis or cystoid 
macular edema; or unwillingness to accept the risk of iris, 
skin, or eyelash changes associated with PGA therapy.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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study design
At baseline (visit 1), patients underwent Goldmann 
applanation tonometry, best-corrected visual acuity testing 
  (Snellen equivalent), and slit lamp biomicroscopy. For 
patients who were eligible for trial participation, both 
solicited and unsolicited adverse events were recorded 
and the solicited symptom survey was administered. The 
symptom survey queried patients about six common ocular 
symptoms, ie, light sensitivity, blurred or dim vision, stinging 
or burning, foreign body sensation, pain, and redness. 
Patients were instructed to administer brinzolamide-timolol 
twice daily (8 am and 8 pm) for 12 weeks in addition to their 
current PGA monotherapy, with the two medications taken at 
least 5 minutes apart. Week 4 (safety) and week 12 (efficacy) 
visits were scheduled within 1 hour of the baseline visit. 
At the week 4 and week 12 visits, Goldmann applanation 
tonometry, best-corrected visual acuity testing (Snellen 
equivalent), and slit lamp biomicroscopy were conducted, 
and both solicited and unsolicited adverse events were 
recorded. In addition, at the week 12 visit, the solicited 
symptom survey was administered, including additional 
questions about the duration of symptoms and tolerability 
of the study   medication. Treatment success was assessed by 
the investigator at the week 12 visit.
statistical analysis
The primary outcome measure was mean IOP change 
at week 12 for the total study population and was ana-
lyzed by a one-way analysis of variance test. The study   
provided a 90% power to detect a difference of 1.5 mmHg 
between baseline IOP and week 12 IOP if at least 40 patients 
were analyzed. The secondary outcome measure was the 
mean IOP change at week 12 across patient PGA subgroups 
(latanoprost, travoprost, bimatoprost, and tafluprost), which 
was analyzed by a paired t-test within a one-way analysis of 
variance test. The study provided an 80% power to detect 
a difference of 2.0 mmHg among subgroups that contain 
at least 17 patients. One-way analysis of variance tests 
were used to analyze visual acuity differences and solicited 
symptom survey differences. All data analyses were two-
sided and used the intent-to-treat population. If both eyes 
qualified for the study, both were treated and analyzed using 
an average eye analysis. If an ineligible eye was treated with 
study medication, that eye was included in the safety analysis 
but not included in the efficacy analysis. An α-level of 0.05 
was used to determine statistical significance. The data were 
analyzed by PRN Pharmaceutical Research Network, LLC 
(Dallas, TX).
Results
As shown in Table 1, 47 patients (90 eyes) were enrolled in 
the study. All participants were Caucasians. Mean age was 
65.8 (range 31–92) years, with nearly all patients (n = 44) 
having a diagnosis of primary open-angle glaucoma and 
receiving bilateral study medication (n = 43). Most patients 
were taking either latanoprost 0.005% (n = 20) or travoprost 
0.004% (n = 20) monotherapy at study enrollment. After 
12 weeks of adjunctive brinzolamide-timolol therapy, the 
mean IOP of the total patient population decreased from 
Table 1 Patient demographics (n = 47)
Demographics n (%)
Age (years)
 # 55 8 (17)
  56–65 15 (32)
  66–75 16 (34)
 $ 76 8 (17)
gender
  Male 16 (34)
  Female 31 (66)
race
  Caucasian 47 (100)
Qualified eye(s)
  OU 43 (91)
  OD 3 (6)
  Os 1 (2)
Diagnosis
  Primary open-angle glaucoma 44 (94)
  Ocular hypertension 3 (6)
Prostaglandin analog therapy
  Latanoprost 0.005% 20 (43)
  Travoprost 0.004% 20 (43)
  Bimatoprost 0.03% 4 (9)
  Tafluprost 0.0015% 3 (6)
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Figure  1  Mean  intraocular  pressure  ±  standard  deviation  of  total  population 
across visits (n = 47).
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22.1 mmHg at baseline to 16.7 mmHg. This mean IOP 
reduction of 5.4 mmHg (24.4%) was both clinically and 
  statistically significant (P , 0.001; Figure 1). This decrease 
in mean IOP at week 12 was maintained across all PGA 
therapy groups (P , 0.05; Figure 2). Of the 90 eligible eyes, 
85.6% had $3mmHg improvement in IOP from baseline. 
Ninety-eight percent of patients (46/47) had a $1 mmHg 
reduction in IOP from baseline to week 12 and adequate 
tolerability.
No significant differences were observed in symptom 
frequency from baseline to week 12 for any of the six 
symptoms solicited (Figure 3). No significant differences 
were noted upon slit lamp biomicroscopy or visual acu-
ity testing. A total of 17 adverse events from six patients 
was reported, of which 10 were drug-related (Table 2). 
One adverse event, gastroenteropathy, was classified 
as serious but was not considered to be related to the 
study drug. The other adverse events deemed not to be 
related to study drug were conjunctival hyperemia (n = 2), 
and one each of beginning chalazion on upper lid, Heli-
cobacter pylori infection, rash under the eye, and anxiety 
attack; all of these adverse events were mild or moderate 
in intensity. Most (n = 7) of the drug-related adverse events 
were mild or moderate in intensity; the severe events were 
one each of bitter taste, burning eyes, and blurred vision. 
None of the drug-related adverse events required any 
treatment, nor did any result in study drug interruption or 
discontinuation.
Discussion
In the current study, patients who were in need of additional 
ocular hypotensive therapy despite PGA monotherapy 
demonstrated a significant reduction in mean IOP with 
an adjunctive fixed combination of brinzolamide-timolol. 
This clinically and statistically significant IOP reduction 
was observed regardless of the type of concurrent PGA 
monotherapy. The fixed combination of brinzolamide-timolol 
alone was shown to produce an approximately 30% reduction in 
IOP (7–9 mmHg) in patients with untreated ocular hypertension 
or glaucoma.7 In this study, it produced a further mean reduction 
of 5.4 mmHg (24.4%) when added to PGA monotherapy, 
demonstrating its usefulness as adjunctive hypotensive therapy. 
This activity is higher than that reported in previous studies of 
single-agent adjunctive therapy, in which mean IOP decreased 
by 5%–21%,11,12 and is within the range of other adjunctive 
fixed combination therapies (23.5%–29.3%).13
In general, the addition of two hypotensive agents as a 
fixed combination to PGA monotherapy was well tolerated in 
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Figure 2 Mean intraocular pressure ± standard deviation of prostaglandin analog 
therapy groups across visits (n = 47).
Notes: †P < 0.05, week 12 vs week 0 (baseline); *P < 0.001, week 12 vs week 0 
(baseline).
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this study. No significant increase in symptom frequency was 
reported at week 12 with the symptom survey, which queried 
light sensitivity, burning/stinging, eye pain, redness, foreign 
body sensation, and blurred/dim vision. Drug-related adverse 
events were not anticipated, based on the well-known safety 
profiles of brinzolamide and timolol monotherapies.14,15 
  Furthermore, the incidence of these adverse events was 
similar to those reported previously with brinzolamide-
timolol use.7 Adverse events were mostly mild or moderate. 
Although three of the 10 drug-related adverse events were 
severe, none resulted in study drug interruption, discontinua-
tion, or required additional treatment. These symptom results 
and safety profile suggest that brinzolamide-timolol can be 
added to PGA monotherapy safely.
As with any clinical study, this trial did have some 
limitations which need to be kept in mind when interpreting 
its results. The design of this transition trial may have 
allowed for an imbalance in compliance with the two 
therapeutic regimens. Studies have demonstrated that drug 
compliance within clinical studies is frequently better 
than drug compliance in the “real world”.16 Thus, the fact 
that the control medication (prior PGA monotherapy) 
was used outside the context of the clinical trial allows 
for the possibility that patients during the clinical study 
(when they used brinzolamide-timolol + PGA) may have 
exhibited increased compliance with that medication 
regimen than with their PGA monotherapy. An increase in 
compliance during the study could improve the efficacy of 
the adjunctive therapy. We used a rather modest definition 
of treatment success ($1 mmHg reduction in IOP with 
adjunctive therapy). Although 98% of patients were 
classified as treatment successes, some of these patients may 
have achieved a decrease in IOP of only marginal clinical 
relevance. However, it is worth noting that more than 85% of 
the 90 treated eyes demonstrated at least a 3 mmHg reduction 
in IOP with the addition of   brinzolamide-timolol. Finally, 
with respect to the safety and tolerability of adjunctive 
brinzolamide-timolol, the short, 3-month duration of the 
study and the limited scope of the solicited symptom survey 
prevent conclusions as to its long-term efficacy and safety.
Nonetheless, this clinical study supports the hypothesis 
that brinzolamide 1%/timolol 0.5% is an effective adjunctive 
therapy when added to a prostaglandin analog in patients 
receiving insufficient IOP reduction from hypotensive 
monotherapy.
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